Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 04:02:50 2024-04-25 pm EDT After market 04:35:25 pm
130.7 USD +2.93% Intraday chart for Merck & Co., Inc. 130.8 +0.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco... Our Logo
The specter of stagflation rears its ugly head again Our Logo
Transcript : Merck & Co., Inc., Q1 2024 Earnings Call, Apr 25, 2024
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat MT
Merck raises annual target ranges CF
Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised MT
(MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65 MT
Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.78B MT
Earnings Flash (MRK) MERCK & CO. Posts Q1 EPS $2.07 MT
Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024 CI
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales RE
Scholz promises support for pharma sector in Germany as Merck invests RE
Hipgnosis' bidding war intensifies as Concord hikes offer for Shakira music owner RE
Hanmi Pharmaceutical Enters into Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. to Evaluate BH3120 in Combination with KEYTRUDA®? (pembrolizumab) CI
Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer MT
BMO Capital Adjusts Price Target on Merck & Company to $148 From $132 MT
Leerink Partners Raises Merck's Price Target to $134 From $129 MT
Zacks Adjusts Price Target on Merck & Company to $132 From $128 MT
Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust CI
Merck & Co Receives a Shareholder Proposal from National Legal and Policy Center CI
Merck & Co Receives a Shareholder Proposal from Kenneth Steiner CI
Transcript : Merck & Co., Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024 09:55 AM
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
127 USD
Average target price
137.6 USD
Spread / Average Target
+8.33%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share